Therapeutic Applications of Curcumin Nanoformulations

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of curcuma longa linn. For centuries, curcumin has exhibited excellent therapeutic benefits in various diseases. Owing to its anti-oxidant and anti-inflammatory properties, curcumin plays a significant beneficial and pleiotropic regulatory role in various pathological conditions including cancer, cardiovascular disease, Alzheimer’s disease, inflammatory disorders, neurological disorders, and so on. Despite such phenomenal advances in medicinal applications, the clinical implication of native curcumin is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics. However, these issues can be overcome by utilizing an efficient delivery system. Active scientific research was initiated in 2005 to improve curcumin’s pharmacokinetics, systemic bioavailability, and biological activity by encapsulating or by loading curcumin into nanoform(s) (nanoformulations). A significant number of nanoformulations exist that can be translated toward medicinal use upon successful completion of pre-clinical and human clinical trials. Considering this perspective, current review provides an overview of an efficient curcumin nanoformulation for a targeted therapeutic option for various human diseases. In this review article, we discuss the clinical evidence, current status, and future opportunities of curcumin nanoformulation(s) in the field of medicine. In addition, this review presents a concise summary of the actions required to develop curcumin nanoformulations as pharmaceutical or nutraceutical candidates.

Original languageEnglish (US)
Pages (from-to)1341-1356
Number of pages16
JournalAAPS Journal
Volume17
Issue number6
DOIs
StatePublished - Nov 1 2015

Fingerprint

Curcumin
Therapeutics
Curcuma
Biological Availability
Pharmacokinetics
Rhizome
Dietary Supplements
Nervous System Diseases
Oxidants
Solubility
Alzheimer Disease
Anti-Inflammatory Agents
Cardiovascular Diseases
Medicine
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Therapeutic Applications of Curcumin Nanoformulations. / Yallapu, Murali; Bhusetty Nagesh, Prashanth Kumar; Jaggi, Meena; Chauhan, Subhash.

In: AAPS Journal, Vol. 17, No. 6, 01.11.2015, p. 1341-1356.

Research output: Contribution to journalArticle

@article{d946e034fbb44d7caf1773954ed0c21b,
title = "Therapeutic Applications of Curcumin Nanoformulations",
abstract = "Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of curcuma longa linn. For centuries, curcumin has exhibited excellent therapeutic benefits in various diseases. Owing to its anti-oxidant and anti-inflammatory properties, curcumin plays a significant beneficial and pleiotropic regulatory role in various pathological conditions including cancer, cardiovascular disease, Alzheimer’s disease, inflammatory disorders, neurological disorders, and so on. Despite such phenomenal advances in medicinal applications, the clinical implication of native curcumin is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics. However, these issues can be overcome by utilizing an efficient delivery system. Active scientific research was initiated in 2005 to improve curcumin’s pharmacokinetics, systemic bioavailability, and biological activity by encapsulating or by loading curcumin into nanoform(s) (nanoformulations). A significant number of nanoformulations exist that can be translated toward medicinal use upon successful completion of pre-clinical and human clinical trials. Considering this perspective, current review provides an overview of an efficient curcumin nanoformulation for a targeted therapeutic option for various human diseases. In this review article, we discuss the clinical evidence, current status, and future opportunities of curcumin nanoformulation(s) in the field of medicine. In addition, this review presents a concise summary of the actions required to develop curcumin nanoformulations as pharmaceutical or nutraceutical candidates.",
author = "Murali Yallapu and {Bhusetty Nagesh}, {Prashanth Kumar} and Meena Jaggi and Subhash Chauhan",
year = "2015",
month = "11",
day = "1",
doi = "10.1208/s12248-015-9811-z",
language = "English (US)",
volume = "17",
pages = "1341--1356",
journal = "AAPS Journal",
issn = "1550-7416",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Therapeutic Applications of Curcumin Nanoformulations

AU - Yallapu, Murali

AU - Bhusetty Nagesh, Prashanth Kumar

AU - Jaggi, Meena

AU - Chauhan, Subhash

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of curcuma longa linn. For centuries, curcumin has exhibited excellent therapeutic benefits in various diseases. Owing to its anti-oxidant and anti-inflammatory properties, curcumin plays a significant beneficial and pleiotropic regulatory role in various pathological conditions including cancer, cardiovascular disease, Alzheimer’s disease, inflammatory disorders, neurological disorders, and so on. Despite such phenomenal advances in medicinal applications, the clinical implication of native curcumin is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics. However, these issues can be overcome by utilizing an efficient delivery system. Active scientific research was initiated in 2005 to improve curcumin’s pharmacokinetics, systemic bioavailability, and biological activity by encapsulating or by loading curcumin into nanoform(s) (nanoformulations). A significant number of nanoformulations exist that can be translated toward medicinal use upon successful completion of pre-clinical and human clinical trials. Considering this perspective, current review provides an overview of an efficient curcumin nanoformulation for a targeted therapeutic option for various human diseases. In this review article, we discuss the clinical evidence, current status, and future opportunities of curcumin nanoformulation(s) in the field of medicine. In addition, this review presents a concise summary of the actions required to develop curcumin nanoformulations as pharmaceutical or nutraceutical candidates.

AB - Curcumin (diferuloylmethane) is a bioactive and major phenolic component of turmeric derived from the rhizomes of curcuma longa linn. For centuries, curcumin has exhibited excellent therapeutic benefits in various diseases. Owing to its anti-oxidant and anti-inflammatory properties, curcumin plays a significant beneficial and pleiotropic regulatory role in various pathological conditions including cancer, cardiovascular disease, Alzheimer’s disease, inflammatory disorders, neurological disorders, and so on. Despite such phenomenal advances in medicinal applications, the clinical implication of native curcumin is hindered due to low solubility, physico-chemical instability, poor bioavailability, rapid metabolism, and poor pharmacokinetics. However, these issues can be overcome by utilizing an efficient delivery system. Active scientific research was initiated in 2005 to improve curcumin’s pharmacokinetics, systemic bioavailability, and biological activity by encapsulating or by loading curcumin into nanoform(s) (nanoformulations). A significant number of nanoformulations exist that can be translated toward medicinal use upon successful completion of pre-clinical and human clinical trials. Considering this perspective, current review provides an overview of an efficient curcumin nanoformulation for a targeted therapeutic option for various human diseases. In this review article, we discuss the clinical evidence, current status, and future opportunities of curcumin nanoformulation(s) in the field of medicine. In addition, this review presents a concise summary of the actions required to develop curcumin nanoformulations as pharmaceutical or nutraceutical candidates.

UR - http://www.scopus.com/inward/record.url?scp=84945489189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945489189&partnerID=8YFLogxK

U2 - 10.1208/s12248-015-9811-z

DO - 10.1208/s12248-015-9811-z

M3 - Article

VL - 17

SP - 1341

EP - 1356

JO - AAPS Journal

JF - AAPS Journal

SN - 1550-7416

IS - 6

ER -